Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.

Abstract

In a controlled trial burn patients at risk of Pseudomonas aeruginosa septicaemia were passively immunised with an immunoglobulin prepared from plasma from healthy human volunteers vaccinated with a polyvalent pseudomonas vaccine; passively immunised and vaccinated; or only vaccinated. In children the mortality was lowest in those passively immunised (0%, 0/18); it was 21% (9/42) in controls. In adults the mortality rate of those receiving immunoglobulin or vaccine was 10% (3/30) or 8.3% (5/60), respectively, compared with 36% (22/61) in controls. Combined vaccine and immunoglobulin treatment gave rather less protection (mortality 13.6%, 3/22) than vaccine alone. Pseudomonas infection of burns was less common in patients who received immunoglobulin than in vaccinated or control patients.

• Authors: R J Jones, E A Roe, J L Gupta
• Journal: Lancet (London, England) (Lancet) Vol. 2 Issue 8207 Pg. 1263-5 (Dec 13 1980) ISSN: 0140-6736 [Print] England
• PMID: 6108445 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bacterial Vaccines
• Immunoglobulins

Topics

• Adolescent
• Adult
• Age Factors
• Bacterial Vaccines (therapeutic use)
• Burns (complications)
• Child
• Child, Preschool
• Clinical Trials as Topic
• Humans
• Immunization, Passive
• Immunoglobulins (therapeutic use)
• Infant
• Middle Aged
• Pseudomonas (immunology)
• Pseudomonas Infections (mortality, prevention & control)
• Risk
• Sepsis (prevention & control)
• Vaccination
• Wound Infection (prevention & control)